Paul Emery Selected Research

Rheumatoid Arthritis

10/2008	Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.
10/2008	Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.
08/2008	Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.
04/2008	Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate.
12/2007	Delay in imaging versus clinical response: A rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis.
12/2007	Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis.
07/2007	Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis.
05/2007	The role of MRI and ultrasound as surrogate markers of structural efficacy of treatments in rheumatoid arthritis.
04/2007	Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
12/2006	Abatacept in the treatment of rheumatoid arthritis.
12/2006	Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.
09/2006	Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
06/2006	Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.
05/2006	Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis.
05/2006	The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
04/2006	Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.
03/2006	Infliximab treatment maintains employability in patients with early rheumatoid arthritis.
03/2006	Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
10/2005	Co-stimulatory blockade as therapy for rheumatoid arthritis.
08/2005	Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis.
08/2005	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
04/2005	Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
03/2005	Adalimumab therapy: clinical findings and implications for integration into clinical guidelines for rheumatoid arthritis.
01/2005	C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
01/2005	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia.
01/2005	Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
12/2004	Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide.
11/2004	Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
06/2004	Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
06/2004	The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.
03/2004	Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.
03/2004	Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR.
12/2003	Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data.
01/2003	Role of adalimumab, a novel TNF antagonist in advancing rheumatoid arthritis control.
07/2002	Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?
06/2002	Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.
03/2002	High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: short-term efficacy correlates with reduction of macroscopic and histologic synovitis.
02/2002	Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging.

Articles by Research Topic

Disease

38	Rheumatoid Arthritis 10/2008 - 02/2002
3	Arthritis (Polyarthritis) 01/2007 - 02/2003
2	Ankylosing Spondylitis 03/2007 - 01/2003
2	Systemic Scleroderma (Systemic Sclerosis) 01/2007 - 11/2002
2	Synovitis 01/2005 - 03/2002
2	Inflammation 04/2004 - 11/2003
1	Chondrocalcinosis (Pseudogout) 02/2008
1	Osteoarthritis 01/2008
1	Psoriasis (Pustulosis Palmaris et Plantaris) 08/2007
1	Disease Progression 07/2007
1	Psoriatic Arthritis 06/2007
1	Pain (Aches) 05/2007
1	Lymphopenia (Lymphocytopenia) 01/2005
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2004
1	Vasculitis (Vasculitides) 10/2003
1	Interstitial Lung Diseases (Interstitial Lung Disease) 11/2002
1	Rheumatic Diseases (Rheumatism) 02/2002

Drug/Important Bio-Agent (IBA)

10	Methotrexate (Mexate)FDA LinkGeneric 08/2008 - 02/2002
8	infliximab (Remicade)FDA Link 06/2007 - 11/2004
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2008 - 07/2002
7	rituximab (Mabthera)FDA Link 10/2008 - 06/2004
6	abatacept (BELATACEPT)FDA Link 04/2008 - 06/2002
6	leflunomide (Arava)FDA LinkGeneric 08/2005 - 02/2002
3	adalimumab (Humira)FDA Link 10/2008 - 01/2003
3	TNFR-Fc fusion protein (etanercept)FDA Link 08/2008 - 01/2005
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 02/2008 - 03/2004
2	Biological Markers (Surrogate Marker)IBA 07/2007 - 05/2007
2	HLA-B27 Antigen (HLA B27 Antigen)IBA 03/2007 - 02/2002
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2002 - 03/2002
1	celecoxib (Celebrex)FDA Link 01/2008
1	Diclofenac (SR 38)FDA LinkGeneric 01/2008
1	Prednisolone (Predate)FDA LinkGeneric 05/2007
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 01/2007
1	zoledronic acid (zoledronate)FDA Link 05/2006
1	Carbon MonoxideIBA 10/2005
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 04/2005
1	Interleukin-7 (Interleukin 7)IBA 01/2005
1	C-Reactive ProteinIBA 01/2005
1	Antinuclear AntibodiesIBA 12/2004
1	IgG Receptors (Fc gamma RI)IBA 04/2004
1	Aggrecans (Aggrecan)IBA 11/2003
1	Collagen Type II (Type II Collagen)IBA 11/2003
1	AngiopoietinsIBA 02/2003
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2003
1	Methylprednisolone FDA LinkGeneric 11/2002

Therapy/Procedure

2	Biological Therapy 03/2007 - 01/2007
2	Stem Cell Transplantation 03/2004 - 01/2004
1	Drug Therapy (Chemotherapy) 06/2004